Perraut R, Chouteau P, Moog C, Bonnemains B, Kieny M P
Laboratoire d'Immunologie Parasitaire, Institut Pasteur de la Guyane Française, Cayenne, French Guiana, France.
Clin Exp Immunol. 1996 Dec;106(3):434-41. doi: 10.1046/j.1365-2249.1996.d01-857.x.
Since the identification of the HIV virus, important advances have been achieved in the definition of potential subunit vaccines. We investigated the immunogenicity of a recombinant gp160 antigen and of two gp41 peptides from HIV-1LAI associated with seven different adjuvant formulations in squirrel monkeys. All animals were immunized twice with gp160 and then with a gp41 peptide using the same formulation. All adjuvants used led to a subsequent antibody response against gp160, and 55% of the animals immunized developed anti-gp160 antibodies that could neutralize the virus in vitro. Specific anti-gp41 antibody response was also observed. Results obtained underlined the key role of the adjuvant formulation in the antibody response against a given part of the immunogen, and indicate that such immunogenicity-related investigation can be carried out conveniently in the squirrel monkey Saimiri sciureus.
自发现艾滋病毒以来，在潜在亚单位疫苗的定义方面取得了重要进展。我们研究了重组gp160抗原以及来自HIV-1LAI的两种gp41肽与七种不同佐剂配方在松鼠猴中的免疫原性。所有动物先用gp160免疫两次，然后使用相同配方用gp41肽免疫。使用的所有佐剂均导致随后针对gp160的抗体反应，并且55%接受免疫的动物产生了可在体外中和病毒的抗gp160抗体。还观察到了特异性抗gp41抗体反应。所获得的结果强调了佐剂配方在针对免疫原特定部分的抗体反应中的关键作用，并表明这种与免疫原性相关的研究可以在松鼠猴（Saimiri sciureus）中方便地进行。
